ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ -- AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors (“Methods and Composition for the Activation of Gamma Delta T cells” US10023880 and US10036040). The third patent is AGT’s first in its HIV Cure program and protects a lentiviral vector and proprietary process for generating autologous cell products for treating HIV (“HIV Pre-Immunization and Therapy” US10036038).
AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.
Clicking the image will take you to the original article